OrthoSpace completes financing — 5 key notes

Laura Dyrda -   Print  |

OrthoSpace completed financing which will facilitate growth in the future.

Here are five things to know:

 

1. The financing was led by HealthpointCapital.

 

2. The financing also included existing investors Smith & Nephew and TriVentures.

 

3. The proceeds will facilitate continued market adoption, clinical study programs and entry into the emerging markets.

 

4. OrthoSpace's flagship product is InSpace, a disruptive technology for treating severe rotator cuff tears. The technology addresses a large growing market segment with limited treatment options for the continuum-of-care for rotator cuff injury.

 

5. The terms of the agreement were not disclosed.

 

"With five years of clinical experience and over 5,000 procedures completed, we have developed a loyal following among surgeons in Europe and Israel," said Assaf Dekel, MD, OrthoSpace's co-founder and medical director.

 

More articles on orthopedic devices:
47 orthopedic & spine devices receive FDA 510(k) clearance in April
Implanet gets FDA clearance for new JAZZ rod sizes—5 things to know
LDR COO sells 1.2k shares in $49k transaction: 5 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers